Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Antibiotic use during coronavirus disease 2019 intensive care unit shape multidrug resistance bacteriuria: A Swedish longitudinal prospective study
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Anaesthesiology and Intensive Care.ORCID iD: 0000-0003-0060-005X
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Anaesthesiology and Intensive Care.ORCID iD: 0000-0001-9146-7965
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology.ORCID iD: 0000-0002-5081-0138
Show others and affiliations
2023 (English)In: Frontiers in Medicine, E-ISSN 2296-858X, Vol. 10, article id 1087446Article in journal (Refereed) Published
Abstract [en]

Objectives: High frequency of antimicrobial prescription and the nature of prolonged illness in COVID-19 increases risk for complicated bacteriuria and antibiotic resistance. We investigated risk factors for bacteriuria in the ICU and the correlation between antibiotic treatment and persistent bacteria.

Methods: We conducted a prospective longitudinal study with urine from indwelling catheters of 101 ICU patients from Uppsala University Hospital, Sweden. Samples were screened and isolates confirmed with MALDI-TOF and whole genome sequencing. Isolates were analyzed for AMR using broth microdilution. Clinical data were assessed for correlation with bacteriuria.

Results: Length of stay linearly correlated with bacteriuria (R2 = 0.99, p ≤ 0.0001). 90% of patients received antibiotics, primarily the beta-lactams (76%) cefotaxime, piperacillin-tazobactam, and meropenem. We found high prevalence of Enterococcus (42%) being associated with increased cefotaxime prescription. Antibiotic-susceptible E. coli were found to cause bacteriuria despite concurrent antibiotic treatment when found in co-culture with Enterococcus.

Conclusion: Longer stays in ICUs increase the risk for bacteriuria in a predictable manner. Likely, high use of cefotaxime drives Enterococcus prevalence, which in turn permit co-colonizing Gram-negative bacteria. Our results suggest biofilms in urinary catheters as a reservoir of pathogenic bacteria with the potential to develop and disseminate AMR.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2023. Vol. 10, article id 1087446
Keywords [en]
UTI, ICU–intensive care unit, COVID-19, MDR–(multidrug resistance), AMR, antibiotic treatment, catheters
National Category
Anesthesiology and Intensive Care Infectious Medicine Clinical Medicine Microbiology in the medical area Public Health, Global Health and Social Medicine
Research subject
Anaesthesiology and Intensive Care; Microbiology; Epidemiology; Urology; Pharmaceutical Microbiology; Clinical Bacteriology; Clinical Pharmacology
Identifiers
URN: urn:nbn:se:uu:diva-496102DOI: 10.3389/fmed.2023.1087446ISI: 000934136200001PubMedID: 36824610OAI: oai:DiVA.org:uu-496102DiVA, id: diva2:1734876
Funder
Swedish Society for Medical Research (SSMF), S18-0174Swedish Research Council, 2018-02376Swedish Research Council, 2014-02569Swedish Research Council, 2014-07606Knut and Alice Wallenberg Foundation, 2020.0182Knut and Alice Wallenberg Foundation, 2020.0241Swedish Heart Lung Foundation, 20210089Swedish Heart Lung Foundation, 20190639Swedish Heart Lung Foundation, 20190637The Swedish Kidney Foundation, F2020-0054Science for Life Laboratory, SciLifeLabAvailable from: 2023-02-07 Created: 2023-02-07 Last updated: 2026-02-02Bibliographically approved

Open Access in DiVA

fulltext(14661 kB)541 downloads
File information
File name FULLTEXT01.pdfFile size 14661 kBChecksum SHA-512
b8aedb1157897e6b534ac06710b9d2a636b700573ba53a5a17b7601d704bb47d359fd4ce6c3f82e383d01f20a6920d6051e5c8fa38a02f7e110bf90d8374588e
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records

Karlsson, Philip A.Pärssinen, JuliaDanielsson, Erik A.Fatsis-Kavalopoulos, NikosFrithiof, RobertHultström, MichaelLipcsey, MiklósJärhult, Josef D.Wang, Helen

Search in DiVA

By author/editor
Karlsson, Philip A.Pärssinen, JuliaDanielsson, Erik A.Fatsis-Kavalopoulos, NikosFrithiof, RobertHultström, MichaelLipcsey, MiklósJärhult, Josef D.Wang, Helen
By organisation
Department of Medical Biochemistry and MicrobiologyAnaesthesiology and Intensive CareIntegrative PhysiologyHedenstierna laboratoryInfection medicine
In the same journal
Frontiers in Medicine
Anesthesiology and Intensive CareInfectious MedicineClinical MedicineMicrobiology in the medical areaPublic Health, Global Health and Social Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 541 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 668 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf